Uncategorized-EN
Results of 62005 study available now
The 62005 study looked at the ten-year progression-free and overall survival in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST). Long-term analysis of the EORTC, ISG, AGITG intergroup Phase III randomized trial on imatinib at two dose levels. Results Study 62005
Read More7th SPAEN Conference 2016 Warsaw/Poland
Interest Group Developed Sarcoma Policy Checklist
On 8th of February 2017 a rare cancer policy debate at the European Parliament took place on how to improve the policy response to rare cancers, with a focus on sarcoma. Representatives from the ​European ​Commission, ​Member States, the ​European ​Parliament, ​industry ​delegates and ​sarcoma ​patients engaged in a policy debate on key challendes for…
Read MoreERNs start work March 1, 2017
Newly established European Reference Networks (ERNs) start their work March 1, 2017 24 thematic ERNs, gathering over 900 highly specialised healthcare units from 26 countries, will begin working together on a wide range of issues. Among them the ERN for Rare Solid Tumours EURACAN. SPAEN, along with other patient advocacy groups for rare…
Read MoreNew Desmoid Trial started in Belgium
eSurge 2016 Summary
On the 15th and 16th of November 2016, 50 surgeons from 13 different countries met in Institut Curie, Paris to attend the fifth edition of the esurge sarcoma surgery masterclass developed and directed by Dr Sylvie Bonvalot (Institut Curie) and Dr Alessandro Gronchi (Istituto di Tumori di Milano). Launched in 2010 as part of the…
Read MoreSurgery With Our Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (STRASS2)
Surgery With Our Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (STRASS2) Agents: Surgery & neoadjuvant chemotherapy Phase III Status Open, recruiting Sponsor EORTC Further information: https://clinicaltrials.gov/ct2/show/NCT04031677 or https://www.eortc.org/research_field/clinical-detail/1809/ This trial to assess whether preoperative chemotherapy followed by surgery improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients. WHO is the…
Read MoreTRC105 in combination with pazopanib vs. pazopanib alone in advanced angiosarcoma (TAPPAS)
This study evaluates the efficacy and safety of TRC105 in combination with pazopanib vs. pazopanib alone in advanced angiosarcomas. Trial name TAPPAS Agents TRC105 and pazopanib Phase III Status Terminated Sponsor Tracon Pharmaceuticals Inc. A randomized phase III trial of TRC105 and pazopanib vs. pazopanib alone in patients with advanced angiosarcoma (TAPPAS).Further information: https://www.clinicaltrials.gov/ct2/show/study/NCT02979899?term=tracon&cond=Angiosarcoma&rank=1&show_locs=Y#locn …
Read MoreTazemetostat in Advanced Epithelioid Sarcoma
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma Agents: Tazemtostat Phase III Status Recruiting Sponsor Epizyme, Inc Further information: https://www.clinicaltrials.gov/ct2/show/NCT04204941?term=tazemetostat&cond=sarcoma&phase=2&draw=2&rank=1 This is an international, double-blind and randomized phase 3 study to evaluate the efficacy and safety of tazemetostat + doxorubicin vs placebo + doxorubicin in patients with advanced epithelioid…
Read MoreIntrigue: DCC-2618 vs sunitinib in advanced GIST after treatment with imatinib
Agents: DCC-2618 (Ripretinib) vs. Sunitinib Phase III Status Closed for recruitment, active Sponsor Deciphera Pharmaceuticals LLC Further information: https://clinicaltrials.gov/ct2/show/NCT03673501 WHO is the trial for? Patients with confirmed advanced or metastatic GIST Patients must have progressed on imatinib or are intolerant to imatinib; patients who had further lines of treatment after imatinib cannot…
Read More